Billy Caldwell Thrives Eight Years After UK Cannabis Law Change

Legal Framework Shift Tied to Single Patient Case

Billy Caldwell's June 2018 medical emergency at Heathrow Airport—where customs officers confiscated his cannabis oil supply—triggered an emergency ministerial order that became the foundation of the UK's 2018 medical cannabis rescheduling. Home Secretary Sajid Javid issued a 20-day license on June 19, 2018. That made Caldwell the first patient in modern UK history to receive a legal prescription for whole-plant cannabis extract. Parliament rescheduled cannabis-based products for medicinal use from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations four months later, effective November 1, 2018.

Under a strict reading of the 2018 regulations, specialist physicians on the General Medical Council register may prescribe cannabis-based medicinal products only when no licensed alternative exists and the patient presents an exceptional clinical need. The National Institute for Health and Care Excellence guidance issued in 2019 restricts reimbursed prescriptions to three narrow indications: treatment-resistant epilepsy in children, chemotherapy-induced nausea, and spasticity in multiple sclerosis. Caldwell's diagnosis—severe myoclonic epilepsy of infancy, also known as Dravet syndrome—falls within the first category.

Current Treatment Protocol and Seizure Outcomes

Caldwell now receives a prescription for cannabidiol oil containing less than 0.2 percent tetrahydrocannabinol, dispensed through a National Health Service specialist clinic in Northern Ireland. His mother, Charlotte Caldwell, told the BBC that Billy hasn't experienced a single tonic-clonic seizure since resuming treatment in mid-2018. That's a stark contrast to the multiple daily seizures he suffered before accessing cannabis therapy. Before 2018, Caldwell's family traveled to Canada and the Netherlands to obtain cannabis oil, incurring costs exceeding £30,000 annually.

The clinical outcome data align with published literature on cannabidiol efficacy in Dravet syndrome. A 2017 randomized controlled trial published in The New England Journal of Medicine found that cannabidiol reduced convulsive-seizure frequency by a median of 38.9 percent compared to placebo in patients with Dravet syndrome. Caldwell's complete seizure cessation represents an outcome at the favorable tail of that distribution.

Systemic Access Barriers Persist Despite Regulatory Change

Fewer than 5,000 patients in the UK hold active medical cannabis prescriptions as of August 2026, eight years after the law changed—a figure patient advocacy groups attribute to restrictive NICE guidance and physician reluctance to prescribe off-formulary. The Drug Science nonprofit estimates that approximately 1.4 million UK patients could benefit from cannabis-based therapies under current clinical evidence, implying a prescription rate below 0.4 percent of the eligible population. Most patients who access medical cannabis do so through private specialist clinics charging £150 to £300 per consultation, with monthly product costs ranging from £200 to £800.

Charlotte Caldwell has testified before three Parliamentary committees since 2019, arguing that the 2018 regulatory framework created a two-tier system in which wealthy patients access treatment while NHS patients face de facto prohibition. The Department of Health and Social Care hasn't amended NICE guidance since its 2019 publication. For full background on this story, see the CannIntel topic hub on UK medical cannabis access.

NHS England's ongoing review of specialist commissioning pathways for rare pediatric epilepsies may deliver the next policy inflection point—the review is expected to conclude in Q4 2026. If it recommends expanding cannabidiol access criteria beyond current NICE parameters, the Treasury will need to model budget impact across an estimated 3,000 to 5,000 pediatric patients with treatment-resistant epilepsy syndromes.